Sector Expert: Christian Glennie

Edison Investment Research

Image: Christian Glennie

Christian Glennie joined the healthcare team at Edison Investment Research in January 2012 and has 11 years' experience covering the global biotech/pharmaceutical sector as an analyst and a journalist. He came to Edison having held senior analyst and editorial roles at EvaluatePharma and EP Vantage. Christian Glennie also has prior experience as a marketing analyst at Zeneca Agrochemicals.



Recent Interviews

Seven Biotech Options that Buck Tradition: Christian Glennie (6/6/13)

Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. What's unusual is that Edison looks for tomorrow's upside in companies still small enough to double, triple and quadruple in value down the line. In this interview with The Life Sciences Report, Edison Biotechnology Analyst Christian Glennie applies his valuation skills to seven innovative biotech and specialty pharma companies and discusses the share-moving catalysts that investors need to know about now.

Recent Quotes

"ATHX's MultiStem in ischemic stroke showed a favorable safety profile."

— Christian Glennie, Edison Investment Research (5/5/15)
more >

"Positive Phase 2 data in ischemic stroke could significantly rerate ATHX stock."

— Christian Glennie, Edison Investment Research (3/5/15)
more >

"We estimate ATHX's MultiStem to hit peak sales of $3B across the US, EU and Japan."

— Christian Glennie, Edison Investment Research (1/12/15)
more >

"ATHX is well positioned in terms of its stage of development and the profile of its MAPCs."

— Christian Glennie, Edison Investment Research (11/24/14)
more >

"Positive Phase 2 data in ischemic stroke could rerate ATHX's stock."

— Christian Glennie, Edison Investment Research (9/24/14)
more >

"ATHX's Phase 2, ischemic stroke study results are expected in Q4/14."

— Christian Glennie, Edison Investment Research (6/30/14)
more >

"Potential FDA clearance for VRS' Aura is a key near-term catalyst."

— Christian Glennie, Edison Investment Research (6/30/14)
more >

"A key, near-term catalyst for VRS is 501(k) FDA clearance for Aura."

— Christian Glennie, Edison Investment Research (6/2/14)
more >

more comments

"ATHX is well capitalized with $45M in cash at Q1/14E."

— Christian Glennie, Edison Investment Research (5/6/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.